Key points from article :
Genoskin can help de-risk antiaging trials with the only live human skin model available for subcutaneous administration testing.
It is paving the way to better, faster, safer drug development.
Provides biotech, pharma, and cosmetics companies with the opportunity to quickly generate reliable human data.
Its new HypoSkin model is the only alternative to animal testing for subcutaneous injections, increasingly popular for drug delivery.
Allows a compound to test efficacy and toxicity, as well for absorption and metabolism studies.
“Our skin comes from consenting patients from plastic surgeries,” Eric Merle, Genoksin’s chief business innovation officer.
“The immune cells remain within the tissue, so it maintains its structure, metabolism, and its ability to repair itself.”
“...experimental window of at least 7 days.”
Continuing to address the key challenge of any ex vivo model – lack of circulation.
Technologies such as Genoskin’s will eventually replace some human trials, even beyond skin treatments.
